Renin-Angiotensin-System (RAS) und COVID-19 – Zur Verordnung von RAS-Blockern
- 22 April 2020
- journal article
- editorial
- Published by Georg Thieme Verlag KG in Deutsche Medizinische Wochenschrift (1946)
- Vol. 145 (10), 682-686
- https://doi.org/10.1055/a-1152-3469
Abstract
Twenty years ago, an enzyme homologous to the previously known angiotensin-converting enzyme (ACE) was identified, and subsequently named ACE2. In the renin-angiotensin system (RAS), ACE2 has counter-regulatory functions against the classical effector peptide angiotensin II, for example in blood pressure regulation and cardiovascular remodeling. However, ACE2 provides an initially unexpected interesting link between virology and cardiovascular medicine. That is, ACE2 represents the binding receptor for the cellular uptake of SARS-CoV and SARS-CoV-2 viruses. Thus, ACE2 is relevant for COVID-19. In this context, it was suspected that therapy with RAS blockers might promote transmission and complications of COVID-19 by upregulation of ACE2 expression. The aim of this short review is, to describe the link between the RAS, particularly ACE2, and COVID-19. Based on our analysis and evaluation of the available findings, we justify our conclusion: important drugs such as ACE inhibitors and angiotensin receptor blockers should continue to be prescribed according to guidelines to stable patients in the context of the COVID-19 pandemic. In der Forschung zur SARS-Epidemie (2003) ergab sich schon damals unerwartet eine neue Verbindung zwischen Virologie und Herz-Kreislauf-Medizin – eine Erkenntnis, die wieder aktuell geworden ist. Denn inzwischen ist bekannt, dass ACE2 auch den Bindungsrezeptor für das neue Virus der COVID-19-Infektion, SARS-CoV-2, darstellt. Sind Medikamente wie ACEI und ARB nun riskant? Der Beitrag erläutert die Zusammenhänge und die Relevanz für den Praktiker.Keywords
This publication has 14 references indexed in Scilit:
- Covid-19 — Navigating the UnchartedThe New England Journal of Medicine, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart FailurePharmacological Reviews, 2019
- 2018 ESC/ESH Guidelines for the management of arterial hypertensionJournal of Hypertension, 2018
- The ACE2/Angiotensin-(1–7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1–7)Physiological Reviews, 2018
- Global Burden of Hypertension and Systolic Blood Pressure of at Least 110 to 115 mm Hg, 1990-2015JAMA, 2017
- The discovery of angiotensin‐converting enzyme 2 and its role in acute lung injury in miceExperimental Physiology, 2008
- Physiology of Local Renin-Angiotensin SystemsPhysiological Reviews, 2006
- Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirusNature, 2003
- A Human Homolog of Angiotensin-converting EnzymeJournal of Biological Chemistry, 2000